9 results
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
1 May 23
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
9:01am
. During his long tenure at Roche and Genentech, Dr. Rousseau built a team solely dedicated to developing innovative treatments for children
PRE 14A
DAWN
Day One Biopharmaceuticals Inc
18 Apr 23
Preliminary proxy
4:05pm
and qualifications of existing directors, tenure, potential director departures and the Company’s evolving strategic objectives
Comprehensive risk … the global oncology franchise, finishing his career there as President, Pfizer Oncology in April 2015. During his tenure at Pfizer, Mr. Nicholson
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
7 Nov 22
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
4:31pm
team with the appointment of Adam Dubow as general counsel. Mr. Dubow joins Day One following a 22-year tenure at Bristol Myers Squibb, where he most
10-K
EX-10.2
50hia55t piu53ajyn
7 Mar 22
Annual report
7:36am
S-1/A
EX-3.1
dh7sol
24 May 21
IPO registration (amended)
6:16am
S-1
EX-3.1
3ybch1x8px oisq3eu
4 May 21
IPO registration
4:12pm
DRS
EX-3.1
vzg3zdll156 a6lqb5
19 Mar 21
Draft registration statement
12:00am
- Prev
- 1
- Next